Anadys Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing small molecule medicines for the treatment of viral diseases and cancer. The company has core expertise in structure-based drug design coupled with medicinal chemistry and Toll-Like Receptor-based small molecule therapeutics. Its clinical development program includes ANA380 for the treatment of HBV, currently in mid-stage clinical development. Anadys Pharmaceuticals also focuses on the development of the ANA975 program for the treatment of HCV and HBV. In addition, it has an oncology program with the oral TLR-7 agonist, ANA773; a direct antiviral HCV program around a series...